March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
110 citations
,
October 2019 in “Translational Andrology and Urology” More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
10 citations
,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
February 2023 in “Global Journal of Reproductive Medicine” Medical treatments for benign prostatic hyperplasia mainly relieve symptoms, while surgery is more effective but not always suitable for elderly patients.
September 2025 in “Consilium Medicum” 5α-reductase inhibitors help manage symptoms of benign prostatic hyperplasia and may also prevent prostate cancer and treat hair loss.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
5 citations
,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
1 citations
,
January 2022 in “Food & Function” Certain Egyptian Sabal fruit extracts may help treat anti-androgenic diseases like benign prostatic hyperplasia.
Dihydrotestosterone (DHT) and its active metabolites play a key role in various diseases, and the development of 5α-reductase inhibitors can help treat these conditions.
295 citations
,
September 2006 in “Cell Cycle” The conclusion is that using drugs to block the TOR pathway might slow aging and prevent age-related diseases.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
21 citations
,
April 2011 in “Physiological Research” Normal levels of DHT can reduce belly fat and increase muscle, but too much can lead to hair loss, prostate issues, and possibly heart disease.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
October 2010 in “Journal of Men's Health” Larger prostate size in older men may be linked to poorer semen quality and fertility issues.
1 citations
,
February 2024 in “Medicine” Eosinophilic cystitis is often misdiagnosed, but accurate diagnosis and treatment improve outcomes.
39 citations
,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Antiandrogens help treat hormone-related conditions in both men and women.
58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
1 citations
,
July 2012 in “Der Urologe” Finasteride effectively reduces prostate size and symptoms in most BPH patients.
June 2024 in “Research Square (Research Square)” Finasteride overdose can cause acute pancreatitis.
Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
7 citations
,
January 2004 in “Drugs of today” 5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.